StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PACBBearishEarningsnews
Materiality pending

Pacific Biosciences (PACB) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

May 9, 2024, 7:38 PM EDT1 sourcesAI-analyzed

AI summary

What happened, with direct paths to the underlying reporting

- PACB reported revenue of $38.81 million, down 0.2% YoY, with EPS -$0.26. - Revenue surprises +0.08% over Zacks Consensus Estimate of $38.78 million. - Key metrics show varied performance in different segments. - Stock performance: -49.6% over past month, Zacks Rank #2 (Buy). Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings

  • PACB reported revenue of $38.81 million, down 0.2% YoY, with EPS -$0.26.
  • Revenue surprises +0.08% over Zacks Consensus Estimate of $38.78 million.
  • Key metrics show varied performance in different segments.
  • Stock performance: -49.6% over past month, Zacks Rank #2 (Buy).

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.